Recurrent fevers, cough, and pulmonary opacities in a middle-aged man

Chest

Volumn 137, Issue 6, 2010, Pages 1465-1469

  Bauer, Philippe R ^a   Zent, Clive S ^a   Aubry, Marie Christine ^a   Ryu, Jay H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ANTIBIOTIC AGENT; CD38 ANTIGEN; CHLORAMBUCIL; CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; BACKACHE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; CYTOPENIA; DISEASE COURSE; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; HYPOTENSION; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MALE; NIGHT SWEAT; ORGANIZING PNEUMONIA; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RECURRENT FEVER; SINGLE DRUG DOSE; SINUSITIS; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 77953302995     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1271     Document Type: Article

References (20)

1. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47(9):1738-1746.
2. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113(8):2110-2118.
3. McDonald V, Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol. 2009;146(3):233-246.
4. Tonelli AR, Lottenberg R, Allan RW, Sriram PS. Rituximab-induced hypersensitivity pneumonitis. Respiration. 2009;78(2):225-229.
5. Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol. 2004;80(2):164-167.
6. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348(26):2690-2691.
7. Lioté H. Organizing pneumonia associated with rituximab: Challenges raised by establishing causality. Joint Bone Spine. 2008;75(3):260-262.
8. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc. 2004;79(7):949-953.
9. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45(11):2321-2325.
10. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301-326. (Pubitemid 39179164)
11. Polverosi R, Maffesanti M, Dalpiaz G. Organizing pneumonia: typical and atypical HRCT patterns. Radiol Med (Torino). 2006;111(2):202-212.
12. Macartney C, Burke E, Elborn S, et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma. 2005;46(10):1523-1526.
13. Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine. 2008;75(3):362-365.
14. Rollins SD, Colby TV. Lung biopsy in chronic lymphocytic leukemia. Arch Pathol Lab Med. 1988;112(6):607-611.
15. Vaiman E, Odeh M, Attias D, Ben-Arie Y, Oliven A. T-cell chronic lymphocytic leukaemia with pulmonary involvement and relapsing BOOP. Eur Respir J. 1999;14(2):471-474.
16. Kalambokis G, Stefanou D, Arkoumani E, Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia. Eur J Haematol. 2004;73(2):139-142.
17. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6-14.
18. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol. 2007;82(10):916-919.
19. Bienvenu J, Chvetzoff R, Salles G, et al; Groupe d'Etude des Lymphomes de l'Adulte. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J. 2001;2(6):378-384.
20. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol. 2005;81(2):169-170.